logo
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors

Yahoo03-04-2025
VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Kα, a key signaling pathway implicated in solid tumor development and progression
Preclinical data support clinical trials with a broad patient population, and may deliver increased efficacy in combination with other RAS/MAPK pathway inhibitors
Approximately 20 percent of all cancers are driven by mutations of the RAS family of genes1
Vividion continues to advance the chemoproteomics technology platform with goal to unlock disease-causing, yet traditionally undruggable targets with precision small-molecule therapeutics
SAN DIEGO & BERLIN, April 03, 2025--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS-driven cancers. Vividion is a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, utilizing innovative discovery technologies to unlock targets with strong disease-link, yet traditionally undruggable and develop small molecule precision therapeutics for devastating cancers and immune disorders.
The new Phase I study (NCT06804824) will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-159642 as a single agent and in combination with either sotorasib or trametinib in patients with advanced solid tumors.
"Despite being a major driver in approximately 20% of cancers, the RAS gene has proven exceptionally difficult to target with drugs, largely due to its essential role in the RAS-PI3Kα signaling pathway, which is vital for healthy cell function," said Jenna Goldberg, M.D., Chief Medical Officer of Vividion. "VVD-159642 is designed and being studied to selectively prevent RAS activation of the PI3Kα pathway, thus blocking oncogenic signaling without disrupting normal cellular function. Preclinical studies of VVD-159642 give us confidence in its potential to inhibit tumor growth while avoiding the on-target toxicities that have limited prior attempts to drug this important target. In addition to providing a more tolerable alternative to current therapies, we believe that VVD-159642 has potential to treat a broad patient population, including in both RAS-mutant and HER2-overexpressed tumors, and may deliver increased efficacy in combination with other RAS/MAPK pathway inhibitors."
"We're excited to bring our fourth innovative oncology asset into the clinic, which not only represents continued validation of Vividion's covalent-first chemoproteomics platform but also provides a potential new treatment option for patients with RAS-driven cancers," said Aleksandra Rizo M.D., Ph.D., Chief Executive Officer of Vividion.
"The team at Vividion is rapidly advancing scientific innovations into clinical development that have the potential to address multiple devastating diseases not reachable by current therapies," said Christian Rommel, Ph.D., Head of Research and Development at Bayer's Pharmaceuticals Division. "The initiation of this clinical trial marks a significant step forward in leveraging Vividion's innovative drug discovery approach to target a highly relevant signaling pathway and bring a potential new treatment option to people suffering from difficult-to-treat cancers."
Vividion also has ongoing Phase I trials evaluating an oral KEAP1 activator in solid tumors and oral STAT3 inhibitor in solid and hematologic malignancies. The company is advancing multiple innovative drug discovery programs toward the clinic and has a rich pipeline of opportunities emerging in early discovery in the fields of oncology and immunology.
About VividionVividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company's platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com.
About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.
Find more information at https://pharma.bayer.com/ Follow us on Facebook: http://www.facebook.com/bayer
aka (2025-0057)
Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Reference:
1. Ian A. Prior et al "The Frequency of RAS Mutations in Cancer". Cancer Res (2020) 80 (14): 2969–2974. Available at: https://aacrjournals.org/cancerres/article/80/14/2969/640657. Accessed: March 2025.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403585991/en/
Contacts
Bayer Global Media Contact:Derin Denham, phone +1 973 610 7324 Email: derin.denham@bayer.com
Contact for media inquiries Bayer U.S.: Elaine Colon, phone +1 732 236 1587 Email: elaine.colon@bayer.com
Vividion Media Contact: Laurie Sherman, phone +1 858 630 8246 Email: media@vividion.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer
ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer

Yahoo

time9 minutes ago

  • Yahoo

ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer

By Karen Roman ReAlta Life Sciences, Inc. said it designated Ellen Lubman as Chief Business Officer to supervise business development, capital formation and corporate strategy. Ms. Lubman has nearly 25 years of experience across small to large-cap private and public biopharmaceutical companies with a track record in strategic, transactional, and operational roles, the company stated. She previously served as Chief Business Officer at Werewolf Therapeutics, Inc. (Nasdaq: HOWL), taking the company through multiple financings including an IPO, it said. 'Ellen is a highly respected executive with a strong track record of building partnerships, raising capital, and developing successful corporate strategies for biotech and pharmaceutical companies,' said David Marek, ReAlta's CEO. 'We are excited to welcome Ellen at such a pivotal moment for our business with all three clinical programs reading out this year.' Ms. Lubman holds an M.B.A. from Stanford Graduate School of Business and a B.A. in Biology from Rutgers College. READ MORE ReAlta Drug Shows Promise in Protecting Newborn Brains from Oxygen Deprivation Injuries Never Miss our Weekly Highlights Contact: Exec Edge Editor@ Click to follow us on LinkedIn Sign in to access your portfolio

EFG Companies: Top Five Questions We Hear From Dealers Reflect State of the Industry
EFG Companies: Top Five Questions We Hear From Dealers Reflect State of the Industry

Yahoo

time9 minutes ago

  • Yahoo

EFG Companies: Top Five Questions We Hear From Dealers Reflect State of the Industry

Challenging Times Demand Sound Counsel During Second Half of 2025 DALLAS, July 29, 2025--(BUSINESS WIRE)--EFG Companies has the ear of over 1,600 retail automotive and powersports dealers and hears the impacts of the current market and economic conditions. Success in the second half of 2025 will require a mixture of strategy, innovation, and preparation to combat the challenging forces disrupting sales and revenue generation. Here are the Top Five Questions we hear from dealer principals daily – and the experienced counsel we share with them. For more information, visit Top Five Questions from Dealers What business changes should we make now, given the uncertain economy? Now is not the time to hunker down. While dealers cannot control market forces such as interest rates, tariffs, supply chain, and increasing inventory constraints, dealership owners can closely evaluate annual reinsurance and revenue generation goals. Dealers should consciously and comprehensively analyze personal wealth creation and profit metrics to ensure strong positions. Our Wealth Builder Profit Participation portfolio and Business Development Assessment process are proven tools for success. How can we mitigate losses from tariffs? A strategic focus on training and recruiting is a powerful weapon to fight the impacts of tariffs. Front-end margins and unit sales are anemic – the opportunity for dealers to shore up their business is through backend gross. To drive increased PRU and penetration, there is a need to modify behaviors that set in during COVID when front-end gross was at record highs. For training to deliver sustainable performance results, there must be a commitment from dealership management to support the processes learned in training and not revert to bad (perhaps more comfortable) habits. Ensuring pay plans are structured to motivate the desired behaviors is also key. How can we drive more traffic to our dealership? Consumer concerns about the economy, employment, and rising inflation will continue to impact dealer sales for the foreseeable future. Edmunds' research shows auto finance metrics have reached record highs. Increasing traffic and online to on-lot sales requires dealers to refocus their people on the fundamentals. Traffic-driving and retention products, such as WALKAWAY® and Drive Forever Worry Free from EFG, give consumers confidence in making a large purchase during challenging times, while increasing buyer loyalty and fixed operations revenue. The questions you should ask are 4-fold: Is it good for your brand? Is it good for the consumer? Is it good for your employees? And does it drive profit? What changes should we make to our processes? Artificial intelligence tools are all the buzz, driven by consumers' growing online purchase habits, says Cox Automotive research. Dealers who focus on value-driven differentiation will overstep the competition. Delivering a "Why Buy Here" message at every customer interaction is key. Training across all divisions to reinforce customer interaction while delivering the right products for each individual customer must be an ingrained process. How can we increase our margins and make more per sale? When front-end margins shrink, backend margins must increase. Culture, behavior, and performance are key drivers that impact results. Dealers set the tone here and must go beyond traditional training methodologies to focus on needs-based selling that delivers results. Our data show that properly trained team members can generate an incremental $206,400 average annual F&I profit per producer per year. "If we take the lessons learned from COVID and the Great Recession, we know the root cause issues impacting dealer profit," said Jennifer Rappaport, CEO of EFG Companies. "Some of today's challenges may be unique, but the underlying strategy is the same. With nearly 50 years of empirical data on training and consumer protection products, we intimately understand the challenges facing automotive and powersports dealers. Our dedication to a results-focused client engagement model that combines F&I products with a model-agnostic reinsurance portfolio has delivered proven results. We feel confident that our counsel will once again ensure our customers successfully weather these challenges." About EFG CompaniesFor nearly 50 years, EFG Companies has provided consumer protection programs for vehicles and residences across seven market channels. The company's strategic intent is to build sustainable market differentiation and profitability for its clients and partners, including dealers, lenders, manufacturers, independent marketers, and agents. EFG's award-winning engagement model is built upon the belief that the company serves as an extension of its clients' management teams, providing ongoing F&I development, training, product development, compliance, and nationally recognized product administration with an ASE-certified claims team. Learn more about EFG at: View source version on Contacts Marcia Barnettmbarnett@ 214-868-8861 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

‘Billionaire Reporter' Launches With Exclusive Coverage of America's Wealthiest
‘Billionaire Reporter' Launches With Exclusive Coverage of America's Wealthiest

Yahoo

time9 minutes ago

  • Yahoo

‘Billionaire Reporter' Launches With Exclusive Coverage of America's Wealthiest

Veteran media executive brings serious journalism to the ultra-high net worth community. LOS ANGELES, July 29, 2025--(BUSINESS WIRE)--Matt Toledo, former Publisher and CEO of the Los Angeles Business Journal, is launching Billionaire Reporter, a new digital media platform dedicated to covering the lives, investments, and influence of billionaires. The daily news outlet provides in-depth reporting on the over 1,000 billionaires in the U.S., tracking their philanthropic initiatives, business decisions, and broader impact on the economy and global society. "Billionaires are some of the most powerful figures in the world, yet their stories are largely untold," said Toledo, Founder and CEO. "Billionaire Reporter goes beyond net worth to reveal what drives the people behind the power." Billionaire Reporter's editorial mission is to deliver intelligent, original journalism that examines the lives and impact of the U.S. ultra-high net worth community. The platform goes beyond headlines to offer a deeper understanding of how billionaires build, spend, and shape the world around them. Coverage spotlights legacy billionaires and the most newly minted whose recent liquidity events or public offerings have moved them into the billionaire status. "Our focus is on thoughtful, fact-based journalism that explores the actions and achievements of billionaires across every major sector from business and finance to philanthropy, science, healthcare, and the arts," said Charles Crumpley, Editor-in-Chief, and award-winning, veteran journalist. "We are bringing depth and context to stories and subjects that are often underreported or misunderstood." Billionaire Reporter will also debut "The Vault", a proprietary, first-of-its-kind index that ranks and profiles America's wealthiest individuals. Updated regularly, the premium subscription product will feature curated data, billionaire biographies, and editorial analysis. "'The Vault' will be a signature destination for those tracking the latest financial news, insights and information at the highest levels of power and influence," added Toledo. Billionaire Reporter plans to expand its content through multimedia offerings launching later this year including original podcasts and interactive video segments featuring interviews with billionaires and industry insiders. "This launch fills a major white space in the business media landscape," said Rachel Lin, senior media analyst at Global Media Insights. "There is growing public and private sector interest in billionaire influence, not just their money, but their impact on markets, innovation, and philanthropy. Billionaire Reporter meets that demand while also creating a valuable opportunity for advertisers looking for direct access to one of the most exclusive audiences in the world." To learn more and sign up for updates, visit View source version on Contacts Media Inquiries:Tracy Williamstracy@ Telephone: (310) 824-9000 Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store